Why African countries with onchocerciasis ivermectin programs show much better COVID-19 results?

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.by Juan ChamieUp to date, there are sixteen ivermectin studies on covid as prophylaxis. All of them validate the effectiveness in preventing a symptomatic disease.[i] The studies also underline a positive dose-response relationship. The results range from near 100% effectiveness in weekly doses to 50% in the 42-day period following a single dose. As onchocerciasis program comprises one dose every half-year, it is reasonable to think that the protection doesn’t last that long. A deeper look could give us a better understanding.

In March 2021, Japanese researchers published a study about African countries and Ivermectin on Covid-19. [ii] In the study, the authors evaluate COVID-19 outcomes in African regions. They split the countries into two groups: A group of countries with ivermectin programs to fight onchocerciasis, and another group with the remaining countries. As an aggregate, countries with the program have had a small fraction of Covid cases and deaths than the aggregation of countries without interventions. After ruling out the age disparities, the au...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee